The Hoosier Oncology BRE09-146 phase 2 trial also demonstrated that adding another PARP1 inhibitor rucaparib to cisplatin did not improve the 2-year DFS benefits in TNBC or gBRCA1/2 m breast cancer with residual disease post-neoadjuvant therapy [147]. Here, PARP1 is linked to breast carcinoma.